MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Garthwaite, G.
Right arrow Articles by Garthwaite, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Garthwaite, G.
Right arrow Articles by Garthwaite, J.

Vol. 61, Issue 1, 97-104, January 2002

Soluble Guanylyl Cyclase Activator YC-1 Protects White Matter Axons from Nitric Oxide Toxicity and Metabolic Stress, Probably through Na+ Channel Inhibition

G. Garthwaite, D. A. Goodwin, S. Neale, D. Riddall, and J. Garthwaite

The Wolfson Institute for Biomedical Research, University College London, London, United Kingdom

In the rat isolated optic nerve, nitric oxide (NO) activates soluble guanylyl cyclase (sGC), resulting in a selective accumulation of cGMP in the axons. The axons are also selectively vulnerable to NO toxicity. The experiments initially aimed to determine any causative link between these two effects. It was shown, using a NONOate donor, that NO-induced axonal damage occurred independently of cGMP. Unexpectedly, however, the compound YC-1, which is an allosteric activator of sGC, potently inhibited NO-induced axonopathy (IC50 = 3 µM). This effect was not attributable to increased cGMP accumulation. YC-1 (30 µM) also protected the axons against damage by simulated ischemia, which (like NO toxicity) is sensitive to Na+ channel inhibition. Although chemically unrelated to any known Na+ channel inhibitor, YC-1 was effective in two biochemical assays for activity on Na+ channels in synaptosomes. Electrophysiological recording from hippocampal neurons showed that YC-1 inhibited Na+ currents in a voltage-dependent manner. At a concentration giving maximal protection of optic nerve axons from NO toxicity (30 µM), YC-1 did not affect normal axon conduction. It is concluded that the powerful axonoprotective action of YC-1 is unrelated to its activity on sGC but is explained by a novel action on voltage-dependent Na+ channels. The unusual ability of YC-1 to protect axons so effectively without interfering with their normal function suggests that the molecule could serve as a prototype for the development of more selective Na+ channel inhibitors with potential utility in neurological and neurodegenerative disorders.


Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
D. R. Riddall, M. J. Leach, and J. Garthwaite
A Novel Drug Binding Site on Voltage-Gated Sodium Channels in Rat Brain
Mol. Pharmacol., January 1, 2006; 69(1): 278 - 287.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics